The aim is to reduce the biopharma’s R&D workforce by more than 35% compared with 2025 levels, with the associated cost ...

Evommune has agreed to pay $30 million to China’s Hinova Pharmaceuticals to get stuck into a niche of preclinical molecular ...

Vivoryon Therapeutics has regained the China rights to its kidney disease prospect as the German biotech’s cash reserves ...

MetaVia has linked its GLP-1/glucagon receptor agonist to reductions in liver fat and body weight in a phase 1 trial.

Ultragenyx is laying off 20% of its workforce and axing drug development programs to cut its annual R&D budget to half of the ...

AbbVie has added another angle to its relationship with Nxera, with the Big Pharma paying $100 million upfront for a phase ...

Originally, Rhythm licensed the melanocortin 4 receptor (MC4R) candidate, known at the time as LB54640, from LG for $80 ...

Charles River Laboratories’ virtual control group (VCG) database will be used in a toxicology study run by French biopharma ...

AbbVie has scrapped a phase 2 solid tumor drug after deciding that the monoclonal antibody was unlikely to best the current ...

Pfizer has axed a phase 2 pulmonary arterial hypertension program on business grounds, dealing a setback to a long-running ...

Teva has given up on a key trial of one of its original lineup of innovative medicines. | Teva has given up on a key trial of ...

Fierce has reached out to Novartis to understand the reasons for ending the collaboration. (iStock / Getty Images Plus) Just 14 months after Novartis signed an $800 million biobucks neuroscience ...